Daiichi Sankyo, AstraZeneca sign $6bn worth deal for DS-1062

This article was originally published here

Currently, DS-1062 is being developed for the treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The TROP2 directed DXd antibody drug conjugate (ADC) is

The post Daiichi Sankyo, AstraZeneca sign $6bn worth deal for DS-1062 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply